Skip to main content
Premium Trial:

Request an Annual Quote

Bovigen to Use Sequenom MassArray to Test Cattle DNA

This article has been updated from a previous version, which incorrectly stated that Sequenom would perform the DNA testing. Bovigen will perform the testing using Sequenom's MassArray system.
NEW YORK (GenomeWeb News) — Bovigen, a cattle genetics specialty company, today said that it has been approved under the US Department of Agriculture's Process Verified Program and that it will use Sequenom's MassArray to test cattle DNA.
The USDA PVP designation will allow Bovigen to make marketing claims about lineage, disease resistance, and feed efficiency.
“DNA technology will increasingly impact every facet of the beef business,” Bovigen CEO Victor Castellon said. He added that the approval verifies the company’s ability to provide sample identification and genetic analysis services.
Bovigen is based in Harahan, La.
Sequenom CEO Harry Stylii said the company sees the business of genetic testing of livestock as a “significant growth opportunity that is in part being driven by government mandate.”   
Financial terms of the agreement were not released.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.